🟢 Spero Therapeutics is trading 7.8% up in pre-market with no clear company-specific catalyst

Spero Therapeutics is trading at $1.25, up 7.75% in pre-market, with no clear company-specific catalyst.

• No new company-specific announcement surfaced for October 6; the latest reported release was October 2 inducement grants, not an evident catalyst for the move.
• The supplied Nasdaq pre-market context was up 0.53%, offering background but not establishing the reason for the stock’s rise.
• No volume or activity-level confirmation is available in the provided price context.